VR

Vipulkumar Rameshchandra Bhagat

Active Director Director DIN 01756677
DIN 01756677 First appointment Nov 1995 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 3 historical roles
Total affiliations 6 Since Nov 1995
Shareholding value •••• Premium profile

About Vipulkumar Rameshchandra Bhagat

Data last updated:

Vipulkumar Rameshchandra Bhagat is a Director at Novo Medi Sciences Private Limited (since 2013), Director at Novo Biologicals Private Limited (since 2023) and Designated Partner at Novo Biosciences Llp (since 2023). The companies operate in Pharma and Paper. The 2 current companies with reported revenue have a combined latest revenue of ₹96.23 Cr; the largest is Novo Medi Sciences Private Limited at ₹96.23 Cr (FY 2023). Earlier, Vipulkumar Rameshchandra Bhagat was a Director at Vhb Medi Sciences Limited (2007–2012) and Director at Vhb Life Sciences Limited (2007–2012) and 1 more.

DIN 01756677
Primary Designation Director
Industry Pharma
First Appointment 10 Nov 1995
Oldest Company Age 13 yrs
Largest company Novo Medi Sciences Private Limited · ₹96.23 Cr (FY 2023)
Combined revenue ₹96.23 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Novo Medi Sciences Private Limited U33110MH2013PTC245027
Director29 Jun 20132013₹96.23 Cr (FY 2023)Active
Novo Biologicals Private Limited U46497MH2023PTC412674
Director23 Oct 20232023₹1,305 (FY 2025)Active
Designated Partner07 Aug 20232023Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Vhb Medi Sciences Limited U24232MH2007PLC174054
Director12 Sep 20072007₹159 Cr (FY 2025)Active
Vhb Life Sciences Limited U74900MH2007PLC171648
Director13 Jun 20072007₹13.99 Cr (FY 2025)Active
Vhb Pharmaceuticals Private Limited U24231MH1995PTC094365
Director10 Nov 19951995Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Novo Medi Sciences Private Limited
Novo Biologicals Private Limited
Novo Biosciences Llp
Vhb Medi Sciences Limited
Premium access

Shareholding and investment profile for Vipulkumar Rameshchandra Bhagat

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vipulkumar Rameshchandra Bhagat

Vipulkumar Rameshchandra Bhagat currently holds 3 directorships: Novo Medi Sciences Private Limited (Director, since 29 Jun 2013, revenue ₹96.23 Cr (FY 2023)); Novo Biologicals Private Limited (Director, since 23 Oct 2023, revenue ₹1,305 (FY 2025)); Novo Biosciences Llp (Designated Partner, since 07 Aug 2023).

Vipulkumar Rameshchandra Bhagat was first appointed on 10 Nov 1995 as Director at Vhb Pharmaceuticals Private Limited. The most recent appointment on record is 23 Oct 2023 at Novo Biologicals Private Limited.

The 2 current companies of Vipulkumar Rameshchandra Bhagat that report revenue have a combined latest revenue of ₹96.23 Cr: Novo Medi Sciences Private Limited ₹96.23 Cr (FY 2023); Novo Biologicals Private Limited ₹1,305 (FY 2025).

Vipulkumar Rameshchandra Bhagat held 3 earlier board appointments: Vhb Medi Sciences Limited (Director, 12 Sep 2007 to 18 Dec 2012); Vhb Life Sciences Limited (Director, 13 Jun 2007 to 18 Dec 2012); Vhb Pharmaceuticals Private Limited (Director, 10 Nov 1995 to 18 Dec 2012).

The current boards of Vipulkumar Rameshchandra Bhagat's companies include Anju Sunil Kaudanya (Novo Medi Sciences Private Limited), Forum Vipulkumar Bhagat (Novo Medi Sciences Private Limited), Karan Vipul Bhagat (Novo Medi Sciences Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available